Posted on: September 6, 2012 by Luisa Beltran
New Mountain will be getting more money back. But this time it’s Ikaria that’s paying out a $172 million dividend.
Tags: ARCH Venture Partners, New Mountain Capital, Venrock Associates
Posted on: July 26, 2012 by Mark Boslet
Siluria Technologies said it closed a $30 million Series C financing led by new investors Bright Capital and Vulcan Capital and joined by existing investors ARCH Venture Partners, The Wellcome Trust, Alloy Ventures, Kleiner Perkins Caufield and Byers, Lux Capital, Altitude Life Science Ventures and Presidio Ventures. The company is developing a technology to convert [...]
Tags: Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Presidio Ventures, Siluria Technologies, Vulcan Capital
Posted on: June 21, 2012 by Connie Loizos
Seattle-based W Fund, a $20 million, university-focused fund that officially closed on May 31, officially launched today, according to its managing directors. The fund aims to back startups spun out of the University of Washington and other state research institution and its decisions will be made by an investment committee that Tom Alberg and Greg [...]
Tags: ARCH Venture Partners, Chad Waite, Greg Gottesman, Luciana Simoncini, Lucinda Stewart, Madrona Venture Group, OVP Venture Partners, Ron Howell, Steve Gillis, Tom Alberg, W Fund, WRF Capital
Posted on: May 14, 2012 by Mark Boslet
Venture capital returns have begun to recover with exits from companies such as LinkedIn, Zynga, Jive Software and Imperva fueling liquidity. Funds from 2007 and 2008 are good examples of the renewal.
Tags: ARCH Venture Partners, Foundry Group, Morgenthaler Partners, Spark Capital, Union Square Ventures, University of Texas Investment Management Co.
Posted on: December 15, 2011 by asormani
San Diego headquartered biotech company Fate Therapeutics has appointed William H. Rastetter as chairman and interim CEO. Rastetter is also a partner in venture capital firm Venrock. Fate Therapeutics has secured venture backing from OVP Venture Partners, Astellas Venture Management, Genzyme Ventures, ARCH Venture Partners, Polaris Venture Partners and Venrock. PRESS RELEASE Fate Therapeutics, Inc. [...]
Tags: ARCH Venture Partners, Astellas Venture Management, Genzyme Ventures, OVP Venture Partners, Polaris Venture Partners, Venrock
Posted on: December 12, 2011 by Luisa Beltran
Groove Biopharma has raised $6 million in series B financing from Alexandria Venture Investments, ARCH Venture Partners, OVP Venture Partners, Versant Ventures, and WRF Capital. Seattle-based Groove Biopharma is a privately held biotech.
Tags: Alexandria Venture Investments, ARCH Venture Partners, Groove Biopharma, OVP Venture Partners, Versant Ventures, WRF Capital
Posted on: November 17, 2011 by cnolan
Agios Pharmaceuticals, a Cambridge, Mass.-based developer of drugs to treat cancer, has sealed a whopping $78 million in fresh capital. The company did not disclose all investors in the Series C round, but said that publicly traded Celgene participated, as did existing backers ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.
Tags: ARCH Venture Partners, Flagship Ventures, Third Rock Ventures
Posted on: October 25, 2011 by PEHub Administrator
Adesto Technologies, a Sunnyvale-based, venture-backed semiconductor company specializing in conductive bridging RAM or CBRAM technology, has raised an undisclosed amount of financing — its third round — led by Altis Semiconductor. The companies current investors, which include Adams Street Partners, ATA Ventures, and Arch Venture Partners, among others, contributed pro-rata in the new round. PRESS RELEASE: [...]
Tags: Adams Street Partners, Adesto Technologies, Altis Semiconductor, ARCH Venture Partners, ATA Ventures
Posted on: September 28, 2011 by PEHub Administrator
Siluria Technologies, the California-based methane conversion company, has landed $20 million in the form of a Series B investment led by the Wellcome Trust, a UK-based foundation. Other investors include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.
Tags: Alloy Ventures, Altitude Life Science Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Lux Capital Management, Presidio Ventures, Wellcome Trust
Posted on: September 27, 2011 by cnolan
Siluria Technologies, a San Francisco-based developer of methane-based alternatives for producing fuels and chemicals normally derived from oil, has raised $20 million in new capital. The Series B round was led by UK-based Wellcome Trust, with participation from Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.
Tags: Alloy Ventures, Altitude Life Science Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Lux Capital, Presidio Ventures, Wellcome Trust